Compass Pathways to Announce First Quarter Financial Results on May 8, 2025

About Compass Pathways

Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthesized psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the US Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD).

Compass is headquartered in London, UK, with offices in New York and San Francisco in the US. We envision a world where mental health means not just the absence of illness but the ability to thrive.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250428993513/en/

Enquiries

Media: Dana Sultan-Rothman, [email protected], +1 484 432 0041

Investors: Stephen Schultz, [email protected], +1 401 290 7324

KEYWORDS: Europe United States United Kingdom North America New York

INDUSTRY KEYWORDS: Research Mental Health Finance Clinical Trials Professional Services Biotechnology Managed Care General Health Health Science

MEDIA: